I just bought these beaten-up growth stocks for my ISA

Edward Sheldon just snapped up two new stocks for his ISA. Both are currently well off their 52-week highs, meaning their valuations have also come down.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now, there are many stocks well off their recent highs. As a result, I’m seeing quite a few attractive investment opportunities.

Here, I’m going to highlight two stocks I’ve snapped up for my ISA in the last few weeks. Both have taken a big hit recently and I see the potential for a rebound.

A buying opportunity

First up is Ergomed (LSE: ERGO). It’s an under-the-radar, founder-led company that provides specialised services to the pharma industry. Operating in over 100 countries, it offers solutions to project management (for drug trials, etc), clinical monitoring, regulatory affairs, and more.

Ergomed’s share price has come down from near 1,400p to around 1,000p since the start of December and I see a lot of appeal in the stock after the fall.

This is a healthcare company that has a fair bit of momentum right now. Last year, the group generated revenue of £145.3m, up 22.5% year on year. And at the end of 2022, the group’s order book was sitting at a £295m record high.

As we look ahead to 2023, demand for our services is high.

Dr Miroslav Reljanović, Ergomed Executive Chairman

The risk here is that funding for biotech customers could dry up if financial conditions continue to tighten. This could impact the stock – which currently has a price-to-earnings (P/E) ratio of about 22 – in the short term.

Taking a long-term view however, I’m confident in the growth story. Over the next decade, the global drug discovery market is projected to grow at around 9% per year.

Huge growth potential

Another stock I bought was Airbnb (NASDAQ: ABNB), which is listed in the US. It operates the world’s largest home rental platform.

There’s a lot to like about this well-known company from an investment perspective, in my view. It has a great product/service for a start. I was reminded of this when I recently took a trip to Australia. Through Airbnb, I was able to find some top-notch accommodation.

Secondly, it has a very powerful brand, so powerful that it has even become a verb. This is a huge competitive advantage.

Third, the company has plenty of growth potential. The beauty of its platform is that it’s really scalable. I see the company as well-placed to benefit from the retirement of the Baby Boomers (who love to travel).

Looking forward to 2023, we’re seeing strong demand in Q1, indicating that consumer confidence to travel remains high.

Airbnb 2022 results

Finally, the company is now profitable. This year, the group is projected to generate earnings per share of $3.30.

Now ,Airbnb shares are well off their 52-week highs. This time last year, they were trading near $165. Today, they’re near $110.

Yet even after this share price weakness, they’re still quite expensive. Currently, the forward-looking P/E ratio here is about 33. This adds risk to the investment case.

I’m convinced that buying now will pay off in the long run though. I think this travel company is just getting started.

Edward Sheldon has positions in Airbnb and Ergomed Plc. The Motley Fool UK has recommended Airbnb and Ergomed Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The key number that could signal a recovery for the Greggs share price in 2026

The Greggs share price has crashed in 2025, but is the company facing serious long-term challenges or are its issues…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Can the Rolls-Royce share price hit £16 in 2026? Here’s what the experts think

The Rolls-Royce share price has been unstoppable. Can AI data centres and higher defence spending keep the momentum going in…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

Up 150% in 5 years! What’s going on with the Lloyds share price?

The Lloyds share price has had a strong five years. Our writer sees reasons to think it could go even…

Read more »

Investing Articles

Where will Rolls-Royce shares go in 2026? Here’s what the experts say!

Rolls-Royce shares delivered a tremendous return for investors in 2025. Analysts expect next year to be positive, but slower.

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Up 40% this year, can the Vodafone share price keep going?

Vodafone shareholders have been rewarded this year with a dividend increase on top of share price growth. Our writer weighs…

Read more »

Buffett at the BRK AGM
Investing Articles

Here’s why I like Tesco shares, but won’t be buying any!

Drawing inspiration from famed investor Warren Buffett's approach, our writer explains why Tesco shares aren't on his shopping list.

Read more »

Investing For Beginners

If the HSBC share price can clear these hurdles, it could fly in 2026

After a fantastic year, Jon Smith points out some of the potential road bumps for the HSBC share price, including…

Read more »

Investing Articles

I’m thrilled I bought Rolls-Royce shares in 2023. Will I buy more in 2026?

Rolls-Royce has become a superior company, with rising profits, buybacks, and shares now paying a dividend. So is the FTSE…

Read more »